NCT05259605Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Summary
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
Eligibility criteria
• Age ≥ legal age of consent • Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest • Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16. • Available MRI/CT scans from primary brain tumour at initial diagnosis • Patient's consent Deceased patient: The clinical data and/or biological material and/or CT/MRI/PET images can be accessed and used if at least one of the following three conditions is met: • The patient agreed beforehand in his/her lifetime to a further use of his/her data and/or biological material and/or CT/MRI/PET images, or, • There is consent of a relative to use data and/or biological material and/or CT/MRI/PET images of the deceased patient, or, • There is a reference to a corresponding legal declaration covering the exemption in case of the impossibility or disproportion of getting access to an informed consent (e.g., causing strain on relatives of deceased patients). Additionally, in all cases the following three points need to be fulfilled: • No documentation of previous objection of the patient to the (re-)use of their data, biological material, CT/MR/PET images for research purposes • A notification to an ethics committee for the re-use of these data, biological material and CT/MRI/PET images • Any other national requirements are fulfilled, if applicable
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland, France, Germany, Italy, Austria, Belgium, Greece, Netherlands, Norway, Portugal, Spain, United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC(Network / cooperative)
- Protocol no.
- EORTC-2013-BTG
- Conditions
- Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors, Germ Cell Tumor, Tumor of the Sellar Region, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Embryonal Tumor, Pineal Tumor, Hemangiopericytoma, Hemangioblastoma, Melanocytic Tumor of CNS
- Interventions
- Other
Treatments studied
- Observational
Locations · 42
- Lausanne, SwitzerlandCentre Hospitalier Universitaire VaudoisRecruiting at this site
- Zurich, SwitzerlandUniversitaetsSpital Zurich - Neurology ClinicRecruiting at this site
- Lyon, FranceCHU Lyon - Hopital neurologique Pierre WertheimerRecruiting at this site
- Marseille, FranceHopital de La TimoneRecruiting at this site
- Paris, FranceHopital la Pitie-SalpetriereRecruiting at this site
- Bochum, GermanyKnappschaft Krankenhaus LangendreerRecruiting at this site
- Bonn, GermanyUniversitaetsklinikum BonnRecruiting at this site
- Cologne, GermanyUniversitaetsklinikum KoelnRecruiting at this site
- Essen, GermanyUniversitaetsklinikum - EssenRecruiting at this site
- Frankfurt, GermanyUniversity Hospital Frankfurt -Senckenberg Institute of NeurooncologyRecruiting at this site
- Jena, GermanyUniversitaetsklinikum JenaRecruiting at this site
- Leipzig, GermanyUniversitaetsklinikum Leipzig-Klinik fuer Strahlentherapie und RadioonkologieRecruiting at this site
- Regensburg, GermanyUniversitaetsklinikum RegensburgRecruiting at this site
- Bologna, ItalyOspedale Bellaria-BolognaRecruiting at this site
- Florence, ItalyAzienda Ospedaliero-Universitaria CareggiRecruiting at this site
- Milan, ItalyIstituto Neurologico Carlo BestaRecruiting at this site
- Milan, ItalyIRCCS Ospedale San RaffaeleRecruiting at this site
- Padova, ItalyIstituto Oncologico VenetoRecruiting at this site
- Roma, ItalyIRCCS-Regina Elena National Cancer CenterRecruiting at this site
- Torino, ItalyOspedale San Giovanni - Dipartimento NeuroscienzeRecruiting at this site
- Innsbruck, AustriaInnsbruck UniversitaetsklinikRecruiting at this site
- Vienna, AustriaUniversitaetsklinikum Wien - AKH uniklinikenRecruiting at this site
- Aalst, BelgiumOnze Lieve Vrouw ZiekenhuisRecruiting at this site
- Anderlecht, BelgiumInstitut Jules BordetRecruiting at this site
- Brussels, BelgiumUniversitair Ziekenhuis BrusselRecruiting at this site
- Liège, BelgiumC.H.U. Sart-TilmanRecruiting at this site
- Roeselare, BelgiumAZ Delta - Campus RumbekeRecruiting at this site
- Athens, GreeceDiagnostic & Therapeutic Center of Athens Hygeia Hospital S.A.Recruiting at this site
- Amsterdam, NetherlandsThe Netherlands Cancer Institute-Antoni Van LeeuwenhoekziekenhuisRecruiting at this site
- Leiden, NetherlandsLeiden University Medical CentreRecruiting at this site
In total, worldwide, all 42 sites listed in the registry are recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: December 17, 2025).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
+ 12 more locations
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.